Biocon has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company (a wholly-owned subsidiary of Astra Industrial Group), a pharmaceutical company based in the Middle East and North Africa (MENA) region, to commercialise its GLP-1 products for treating diabetes and chronic weight management, in select countries of the Middle East.

Under the terms of the agreement, Biocon will develop and manufacture the products whilst Tabuk Pharmaceuticals will hold the marketing authorisation rights, and be responsible to register, import, and promote them in the region. The agreement also provides for a provision to expand to other GLP products, as well as the option of a tech transfer that will enable localised manufacturing at a later stage.